TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group.
Yeung DT, et al. Among authors: trotman j.
Blood. 2015 Feb 5;125(6):915-23. doi: 10.1182/blood-2014-07-590315. Epub 2014 Dec 17.
Blood. 2015.
PMID: 25519749
Free PMC article.
Clinical Trial.